Chemotherapy News and Research

Latest Chemotherapy News and Research

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Researchers at the Moffitt Cancer Center have found that delayed tumor growth and enhanced survival of mice bearing melanoma were possible by blocking the reconstitution of myeloid-derived suppressor cells and Tregs (suppressors of anti-tumor activity) after total body irradiation had eliminated them. Blocking myeloid-derived suppressor cells and regulatory T-cell reconstitution improved adoptive T-cell therapy, an immunotherapy designed to suppress tumor activity.

12 Dec 2012

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Aeterna Zentaris Inc. today announced that final Phase 2 data demonstrated that the combination of perifosine, its oral AKT inhibitor, and sorafenib, was well tolerated by heavily pretreated patients with relapsed/refractory lymphomas.

12 Dec 2012

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Astellas Pharma Inc. and Ambit Biosciences Corporation announced today that the results from a completed Phase 2 study with the investigational FLT3 inhibitor, quizartinib (AC220), as an oral monotherapy treatment regimen in patients with relapsed or refractory acute myeloid leukemia (AML) were presented at the 54th Annual Meeting of the American Society of Hematology (ASH).

11 Dec 2012

Studies examine current treatment standards for patients with clotting disorders

Studies presented today at the 54th Annual Meeting of the American Society of Hematology (ASH) examine current treatment standards for patients with clotting disorders in an effort to improve outcomes.

11 Dec 2012

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

A two-prong approach combining ibrutinib and rituximab (Rituxin) to treat aggressive chronic lymphocytic leukemia (CLL) produced profound responses with minor side effects in a Phase 2 clinical trial at the University of Texas MD Anderson Cancer Center.

11 Dec 2012

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma and the seventh most frequently diagnosed cancer. The most chemotherapy resistant form of DLBCL, called activated B-cell - DLBCL (ABC-DLBCL), remains a major therapeutic challenge.

11 Dec 2012

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

A new drug for patients with acute myeloid leukemia (AML) marked by a specific type of genetic mutation has shown surprising promise in a Phase II clinical trial.

11 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Radiation and chemotherapy can pack a powerful punch against all kinds of cancers. Those who survive, however, are often left with bad news: Their treatments have rendered them infertile.

11 Dec 2012

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Young patients with an aggressive form of leukemia who are likely to relapse after chemotherapy treatment can significantly reduce those odds by receiving additional courses of chemotherapy, suggest the findings of a clinical trial led by investigators at Dana-Farber/Children's Hospital Cancer Center in Boston.

11 Dec 2012

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

Ligand Pharmaceuticals Incorporated announced today that it has initiated a pivotal trial of Captisol-enabled, propylene glycol-free (PG-free) high-dose melphalan as a conditioning treatment prior to autologous transplant for patients with multiple myeloma.

11 Dec 2012

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Liposarcoma, the most common type of sarcoma, is an often lethal form of cancer that develops in fat cells. It is particularly deadly, in part, because the tumors are not consistently visible with positron emission tomography (PET) scans that use a common probe called FDG and because they frequently do not respond to chemotherapy.

11 Dec 2012

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Merrimack Pharmaceuticals, Inc. today announced Phase I clinical trial results for MM-302, the company's novel agent for the treatment of advanced HER2 positive (HER2+ or ErbB2+) breast cancer.

11 Dec 2012

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Celgene International Sàrl today announced that results from a study evaluating the combination of REVLIMID (lenalidomide) plus VIDAZA (azacitidine) in patients 60 years or older with untreated acute myeloid leukemia (AML) were presented at the American Society of Hematology annual meeting in Atlanta, GA.

11 Dec 2012

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

The American Cancer Society has awarded a four-year, $720,000 grant to Boston College Associate Professor of Biology Marc-Jan Gubbels for research into potential new drugs that can prevent the onset of toxoplasmosis in cancer patients with weakened immune systems.

10 Dec 2012

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

New positive Phase II results from an interim analysis of the randomised Phase I/II study involving the company's investigational haematology/oncology compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy were presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, USA.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

FGFR1 amplification heralds poor prognosis in SCCL

Amplification of the fibroblast growth factor receptor 1 gene independently predicts poor outcomes in patients who have undergone resection of squamous cell lung cancer, research shows.

10 Dec 2012

Chemotherapy News and Research

Latest Chemotherapy News and Research

Blocking myeloid-derived suppressor cells after lymphopenia improves adoptive T-cell therapy

Final data from Aeterna Zentaris’ perifosine plus sorafenib Phase 2 study on lymphomas

Astellas, Ambit announce results from quizartinib Phase 2 study on acute myeloid leukemia

Studies examine current treatment standards for patients with clotting disorders

Combination of ibrutinib and rituximab shows promise against chronic lymphocytic leukemia

Weill Cornell research team develops new experimental drug therapy to target DLBCL

Quizartinib shows promise against acute myeloid leukemia in Phase II trial

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

Transplanting spermatogonial stem cells could restore fertility in male cancer patients

Intensified chemotherapy can reduce risk of relapse in pediatric patients with B-ALL

Ligand commences PG-free melphalan pivotal trial in multiple myeloma

FAC PET identifies liposarcoma tumors that are sensitive to chemotherapy

Merrimack announces results from MM-302 Phase I trial on advanced HER2 positive breast cancer

Celgene announces results from REVLIMID plus VIDAZA phase II study on AML

Preliminary results from Boehringer Ingelheim’s volasertib Phase II study on AML

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Boston College professor to research into new drugs that can prevent onset of toxoplasmosis

Boehringer Ingelheim to commence volasertib plus LDAC Phase III study for AML

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

FGFR1 amplification heralds poor prognosis in SCCL

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in